COCP

Rating neutralAI Memo

Cocrystal

As of 2026-07-31/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-31 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

CDI-988 Phase 1b challenge-study data • 2026-10-29

Base target: $1 / p=45% prob

Biggest risk

The company remains a low-coverage microcap biotech with binary clinical risk, no disclosed data-readout date, and limited evidence of near-term revenue or commercialization. The June CEO appointment adds transition and execution uncertainty [#SEC-8K-2026-06-03].

Invalidation

Break below $0 or thesis failure.

What would change my mind?

CDI-988 is advancing through a human-challenge Phase 1b study, has Fast Track designation, and could generate a meaningful re-rating if clinical data are positive. The influenza SBIR award provides non-dilutive support but is secondary to CDI-988.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-07-31

Base target

p=45%

Bull target

p=20%

Bear target

p=35%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Fast Track development execution
Influenza SBIR program progression
CDI-988 is advancing through a human-challenge Phase 1b study, has Fast Track designation, and could generate a meaningful re-rating if clinical data are positive.

BearKey bullets

Development-stage financing and potential dilution remain material risks for a roughly $11 million biotechnology company.
Leadership transition and execution risk increased following the June 2026 CEO appointment [#SEC-8K-2026-06-03].
No clinical readout date is disclosed, limiting forward visibility and increasing event-timing risk.

WatchKey bullets

CDI-988 Phase 1b challenge-study data

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $1 (p=45%)

Target spread vs base: +123% / -46%

Scenario probabilities

Bull Target: $1 (p=20%)Base Target: $1 (p=45%)Bear Target: $0 (p=35%)

Commentary

Primary disclosures are constructive on pipeline progress, Fast Track designation, and SBIR funding [#PR-EARNINGS-2026-05-15]. However, current news, social, options, insider, and analyst-revision coverage is sparse, and no reliable post-release market reaction is available. The deterministic signal is negative, so this remains a low-conviction monitoring view rather than a bullish thesis.

As of 2026-07-31 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Fast Track development execution
Influenza SBIR program progression

Scenarios

Bull Target (Scenario probability)

$1 / p=20% prob

Base Target (Scenario probability)

$1 / p=45% prob

Bear Target (Scenario probability)

$0 / p=35% prob

Analysis 2026-07-31 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-29
CDI-988 Phase 1b challenge-study data
The Phase 1b norovirus challenge study completed its first cohort and enrolled prevention and treatment cohorts. Efficacy, safety, viral-shedding, or pharmacokinetic data could be the principal value inflection, but no readout date is disclosed [#PR-EARNINGS-2026-05-15].
Prob 45.00% • Move 55.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Fast Track development execution
2027-07-31
FDA Fast Track designation for CDI-988 may improve regulatory interaction and development cadence, although its value remains dependent on credible clinical results [#PR-EARNINGS-2026-05-15].
Prob 60% • Move 20% • Priced-in 50%
Influenza SBIR program progression
2027-07-31
Cocrystal received an initial $225,000 SBIR Phase I payment for influenza A and B lead generation; successful completion could support a Phase II application, with modest near-term valuation impact [#PR-EARNINGS-2026-05-15].
Prob 45% • Move 10% • Priced-in 20%

Risks

Development-stage financing and potential dilution remain material risks for a roughly $11 million biotechnology company.
Leadership transition and execution risk increased following the June 2026 CEO appointment [#SEC-8K-2026-06-03].
No clinical readout date is disclosed, limiting forward visibility and increasing event-timing risk.
Phase 1b CDI-988 efficacy, safety, viral-shedding, and pharmacokinetic outcomes could disappoint or be delayed.
The peer set is loose and analyst coverage, social coverage, and trusted post-release market-reaction evidence are unavailable.

Peers

Symbol	Summary
BIVI	Loose same-sector microcap comparator; useful mainly for event volatility and financing context, not as a direct antiviral peer.
CMMB	Same-sector microcap biotechnology comparator with limited operating overlap; clinical and capital-markets risk are the main points of comparison.
KPRX	Small-cap biotech comparator with weak direct overlap; useful for assessing binary development and liquidity risk.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-31

Loading AI feed…

Symbol

Summary

BIVI

Loose same-sector microcap comparator; useful mainly for event volatility and financing context, not as a direct antiviral peer.

CMMB

Same-sector microcap biotechnology comparator with limited operating overlap; clinical and capital-markets risk are the main points of comparison.

KPRX

Small-cap biotech comparator with weak direct overlap; useful for assessing binary development and liquidity risk.